Featured News

TRV-01 is the only technology designed to address the root causes of diabetic foot disease.

Triovance, one of eight private company finalists in the highly competitive.

Triovance has been selected for the INCIDE Pharma & Healthtech Booster Program

Company is on track to move into the clinic with TRV-01, a genetically modified cellular dressing.

Triovance is honored to be presenting at the Startup Spotlight of the 26th American Society of Gene and Cell Therapy

This study evaluated a novel skin graft (TRV-01) developed to improve the wound healing process in a glycated microenvir